5 results about "Cerebral Malaria" patented technology

The present invention relates to pharmaceutical preparations containing as active ingredients 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives in combination with clindamycin and artesunate for the treatment of malaria, in particular for the acute therapy of cerebral malaria, and to an associated dosage, in particular for the patient group of children.

The invention relates to application of a TNF-alpha antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention. In order to solve the problems that in the prior art, the drug resistance of chemical drugs is prominent, efficient vaccines are lacked, and mosquito-stage transmission blocking means are insufficient, TNF-alpha antibodies are injected into plasmodium infected hosts to block binding of host TNF-alpha and mosquito wengen receptors, so that IMD channels are activated, expression of anti-malarial effector factors TEP1 is promoted, and development of plasmodium in mosquito bodies is inhibited; meanwhile, the occurrence rate of host cerebral malaria is reduced, and the transmission blocking effect can be synergistically enhanced by combining with the anti-Pfs25 antibody. The method is accurate in targeting, specifically intervenes a TNF-alpha signal channel, and avoids non-specific damage; dual protection: synchronously blocking mosquito propagation and preventing severe malaria of a host; the blocking efficiency is remarkably improved by combining with the anti-Pfs25 antibody, and a new strategy is provided for malaria prevention and control.

The disclosure belongs to the technical field of biomedicine, and specifically relates to an application of DHA@ZIF-8 in the treatment of experimental cerebral malaria. In the disclosure, an experimental cerebral malaria model is first established. Subsequently, DHA@ZIF-8 is used for treatment in the model, and the therapeutic efficacy of the nanodrug against experimental cerebral malaria is evaluated using behavioral, pathological, and molecular biological techniques. In the disclosure, the use of ZIF-8 as a carrier achieves the effect of slowly releasing the drug, prolonging the duration of action of the drug in vivo, so as to more effectively kill Plasmodium. Compared with natural administration, this approach extends the duration of action of DHA.

The disclosure belongs to the technical field of biomedicine, and specifically relates to an application of Akkermansia muciniphila (AKK) in the amelioration and treatment of cerebral malaria caused by Plasmodium berghei. The disclosure aims to evaluate the efficacy of AKK alone or in combination with adjuvant drugs (dihydroartemisinin, rapamycin, and atorvastatin) in ameliorating and treating experimental cerebral malaria in an experimental cerebral malaria model. The results indicate that AKK, whether used alone or in combination with drugs, can effectively ameliorate behavioral deficits and immunopathological damage of each organ, lower parasitemia levels, and prolong survival period of mice. Compared with the use of drug alone, the combination therapy can effectively treat the experimental cerebral malaria. The disclosure is the first to propose the concept of bacterial-drug synergy concept, and provides a solution to the treatment of human cerebral malaria on the basis of the concept.